SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid concerns over escalating trade tensions between the U.S. and China, with potential tariff implementations looming and some community members fearing a market downturn reminiscent of previous corrections. Discussions include the impact of potential actions from Trump and Powell, and whether current market froth is justified by AI optimism. Some traders are closely watching technical indicators and bracing for volatility ahead of bank earnings and key economic data.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid discussions about market manipulation and potential trade war impacts, with community members debating whether recent price dips represent buying opportunities or signs of a larger correction. Concerns about leveraged positions and insider activity are also circulating, while some analysts maintain a bullish long-term outlook. The digital asset's performance is being closely watched in relation to traditional markets and geopolitical developments.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to renewed US-China trade war concerns sparked by China's sanctions on a Korean shipbuilder and the potential for further tariff escalations, creating market volatility. Community discussions revolve around whether these movements are news-driven rather than technical, and whether Trump's actions will reverse the current downturn. Overall sentiment seems mixed, with some expecting a bounce while others anticipate further drawdowns.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst ($BCRX) is trending amid news of its acquisition of Astria Therapeutics ($ATXS) to bolster its HAE portfolio, a move that has sparked mixed reactions. While some investors see long-term growth potential, others express concerns about the acquisition's cost and potential impact on profitability, leading to active discussions about the company's future direction and valuation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

$CRML is trending as the U.S. aims to secure rare earth elements and reduce reliance on China, sparking community interest in resource independence and potential government support. Discussions revolve around the company's assets in Greenland and the potential for significant growth in a sector deemed critical for national security. Some traders are pointing to a large move in a related ticker, $CLIK, as a reason for caution.

Nova Minerals Ltd. engages in the exploration and development of mineral properties. Its projects include Estelle Gold, RPM, Korbel, Train, Stoney and Studies projects. The company was founded in January 1987 and is headquartered in Melbourne, Australia.

Nova Minerals Limited - ADR

Nova Minerals is trending as discussions revolve around its potential to become a key domestic antimony supplier, especially after the U.S. Department of War awarded funds to Alaska Range Resources (ARR), its subsidiary, to secure the antimony supply chain. The community is focused on the company's unique position with both antimony and gold prospects, viewing it as undervalued compared to other rare earth plays. Some investors express enthusiasm about NVA's long-term growth potential given its Alaskan mining assets.

Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.

Greenwave Technology Solutions Inc

GWAV is experiencing significant volatility, with community members actively debating its potential for a short squeeze amid filing delays and reverse split speculation. Some traders are capitalizing on the price swings, while others express concerns about the company's financials and management. The stock's low float is also a key point of discussion, contributing to its volatile nature.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending due to progress in developing GaN and SiC power devices for NVIDIA's next-gen AI factory architecture, specifically supporting the 800 VDC power architecture. The community is focused on the potential for increased efficiency and power density in AI data centers, with some speculating about a possible short squeeze given the stock's high short interest. Some traders are drawing parallels to other AI-related stocks and anticipating further upside.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending following the release of its Q3 2025 earnings, which revealed profits boosted by investment banking and trading. Community members are actively discussing the better-than-expected revenue and trading results, while also pointing out a net reserve build. Some are speculating on the potential impact of the earnings on the broader market.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as quantum computing stocks experience a surge, fueled by a major financial institution's planned investments in the sector. The community is actively debating the stock's valuation amid this hype, with some citing potential for further gains while others warn of a possible correction and overvaluation. Discussions range from potential short squeezes to comparisons with previous market bubbles.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug...

Zai Lab (ZLAB) announced on Wednesday that it plans to await the results of a trial evaluating Bemarituzumab in combination with Nivolumab and chemotherapy before filing for regulatory approval for the experimental cancer drug.The data from the trial is expected by the end of 2025 or the first half of 2026, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0903/2025090302254.pdf">said</a> in a filing with the Hong Kong stock exchange. Nasdaq-listed <a href="https://stocktwits.com/symbol/ZLAB">shares of Zai Lab</a> were down 4% at the time of writing.On Stocktwits, retail sentiment around ZLAB stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.The announcement from the company follows its partner Amgen's (AMGN) completion of the final analysis of the late-stage trial evaluating Bemarituzumab in combination with Chemotherapy in first-line gastric cancer.Amgen <a href="https://stocktwits.com/news-articles/markets/equity/amgen-cancer-drug-improves-survival-in-late-stage-trial/chmZZAcRR79">said</a> in late June that Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival as compared to placebo plus chemotherapy in people living with certain types of unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer. Overall survival refers to the total length of time a patient with cancer remains alive after diagnosis or the initiation of treatment.However, Zai Lab said on Wednesday that, upon final analysis of the trial, the magnitude of the previously observed survival benefit was reduced, leading the company to await the results of another trial.Zai Lab holds co-development and commercialization rights for Bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan.ZLAB shares are up 22% this year and approximately 66% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-reports-near-four-percent-jump-in-us-vehicle-sales-in-august/chwT6RHRd8r">Ford Reports Near 4% Jump In US Vehicle Sales In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Zai Lab company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug

The company holds co-development and commercialization rights for Bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan.

Equity

The company holds co-development and commercialization rights for Bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan.


Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025...

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class...

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that Chinas National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of...

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating a clinically meaningful...

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and...

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and...

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Zai Lab Limited - ADR

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$31.23
Prev Close	$30.24
Open	$31.38
Dividend Yield	0.00%
50-Day Moving Average	$33.49
Beta	1.11
Avg. Volume	870,824.48
PE Ratio	-14.77

52-Week High	$44.34
52-Week Low	$23.82
Market Capitalization	$28.37B
EPS (Annual)	-$2.60
Price to Book	4.20
Revenue Per Employee	$213,583.80
Enterprise Value/EBITDA	N/A

ZLAB
Zai Lab Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZLAB News

ZLABZai Lab Ltd